ArticleGene therapy2009
Generation of optimized and urokinase-targeted oncolytic Sendai virus vectors applicable for various human malignancies.
Article in Gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy.Nature protocols · 2024Review
- Syncytia Formation in Oncolytic Virotherapy.Molecular therapy oncolytics · 2019Review
- Oncolytic virotherapy for urological cancers.Nature reviews. Urology · 2016Review
- Oncolytic Sendai virus-based virotherapy for cancer: recent advances.Oncolytic virotherapy · 2015Review
- Non-transmissible Sendai virus vector encoding c-myc suppressor FBP-interacting repressor for cancer therapy.World journal of gastroenterology · 2014Article
- Attenuated and protease-profile modified sendai virus vectors as a new tool for virotherapy of solid tumors.PloS one · 2014Article
- Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Frontiers in immunology · 2014Review
- Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine.Current gene therapy · 2012Review
- BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression.Molecular therapy : the journal of the American Society of Gene Therapy · 2012Article
- Oncolytic virotherapy for pancreatic cancer.Expert reviews in molecular medicine · 2011Review
- Article
- Urokinase-targeted fusion by oncolytic Sendai virus eradicates orthotopic glioblastomas by pronounced synergy with interferon-β gene.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Article
- Paramyxovirus entry and targeted vectors for cancer therapy.PLoS pathogens · 2010Article
- Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency.Molecular therapy oncolyticsArticle
- Oncolysis by paramyxoviruses: preclinical and clinical studies.Molecular therapy oncolyticsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously reported the development of a prototype 'oncolytic Sendai virus (SeV) vector' formed by introducing two major genomic modifications to the original SeV, namely deletion of the matrix (M) gene to avoid budding of secondary viral particles and manipulation of the trypsin-dependent cleavage site of the fusion (F) gene to generate protease-specific sequences. As a result, the 'oncolytic SeV' that was susceptible to matrix metalloproteinases (MMPs) was shown to selectively kill MMP-expressing tumors through syncytium formation in vitro and in vivo. However, its efficacy has been relatively limited because of the requirement of higher expression of MMPs and smaller populations of MMP-expressing tumors. To overcome these limitations, we have designed an optimized and dramatically powerful oncolytic SeV vector. Truncation of 14-amino acid residues of the cytoplasmic domain of F protein resulted in dramatic enhancement of cell-killing activities of oncolytic SeV, and the combination with replacement of the trypsin cleavage site with the new urokinase type plasminogen activator (uPA)-sensitive sequence (SGRS) led a variety of human tumors, including prostate (PC-3), renal (CAKI-I), pancreatic (BxPC3) and lung (PC14) cancers, to extensive death through massive cell-to-cell spreading without significant dissemination to the surrounding noncancerous tissue in vivo. These results indicate a dramatic improvement of antitumor activity; therefore, extensive utility of the newly designed uPA-targeted oncolytic SeV has significant potential for treating patients bearing urokinase-expressing cancers in clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.